Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556954 · ClinicalTrials.gov registry record
Diabetic Foot Ulcers Microbiome and Pathogen Identification
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 103
- Enrollment target
NCT05556954: Completed study, sponsored by University of Michigan.
NCT05556954 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05556954 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 103 participants
- Enrollment target
Study Summary
This research is being done because people with diabetes have reduced healing capacity and prone to develop infections of foot wounds. This can be problematic because wounds that become infected may result in amputation and more severe complications. New evidence suggests that a better understanding of the microbiome of wounds (e.g., bacterial presence) may provide information about wound healing and provide an earlier opportunity to identify an individual who may be prone to develop diabetic foot infection in their wound. Therefore, the purpose of this study is to evaluate the role of the microbiome of the diabetic foot ulcer in development of infection and wound healing. Once the role of the microbiome is confirmed, progress towards the prevention and treatment of diabetic foot ulcers and complications may be possible.
Interventions
- PROCEDURE Wound debridement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2025-06-04 |
What the finished NCT05556954 record still lists
NCT05556954 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Wound debridement is the first listed.
NCT05556954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05556954 about?
NCT05556954 is a clinical study titled "Diabetic Foot Ulcers Microbiome and Pathogen Identification". This research is being done because people with diabetes have reduced healing capacity and prone to develop infections of foot wounds. This can be problematic because wounds that become infected may result in amputation and more severe complications. New evidence suggests that a better understanding...
What is the current status of trial NCT05556954?
This trial is currently completed. The enrollment target is 103 participants. The study started on 2022-10-13. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT05556954?
The interventions under investigation include: Wound debridement (PROCEDURE).
Who is sponsoring clinical trial NCT05556954?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI